


DECL55.1CP2DV



RECEIVED
OCT 01 2002
TECH CENTER 1600/2900

10
gmb

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Moser, et al.)	Group Art Unit 1633
)	
App. No.	:	09/802,397)	
)	
Filed	:	March 9, 2001)	
)	
For	:	DENDRITIC-LIKE)	
		CELL/TUMOR CELL)	
		HYBRIDS AND)	
		HYBRIDOMAS INDUCING)	
		AN ANTI-TUMOR)	
		RESPONSE)	
)	
Examiner	:	Unknown)	
)	

PETITION TO MAKE SPECIAL UNDER 37 C.F.R. § 1.102(d)

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Applicants hereby petition the Commissioner to make the present application special in accordance with 37 C.F.R. § 1.102(d) and to advance the present application for examination based on the invention's contribution to the treatment of cancer.

A Petition to Make Special was filed in regard to the above-captioned patent application on September 19, 2002, however the incorrect application number and filing date were noted on the second page of the petition. Applicants file the present petition, containing the correct application number and filing date indicated on page 2, for the sake of clarity.

The present invention relates to dendritic cell/tumor cell hybrids which are capable of inducing an anti-tumor response *in vivo* when administered to a cancer patient in need of treatment. Cells isolated or derived from the specific tumor against which an immune response is needed are fused with dendritic cells or dendritic-like cells, thus producing a dendritic cell/tumor cell hybrid. Several embodiments of these hybrids are summarized in pages 28-30.

Appl. No. : 09/802,397
Filed : March 9, 2001

The hybrids exhibit characteristics of both the dendritic cell and the tumor cell, thus the hybrid will illicit an immune response, either *in vivo* or *in vitro*, against the tumor fusion partner. The immune response contributes to the rejection of the residual tumor in the patient, when the hybrids are administered *in vivo*. For induction of an anti-tumor response *in vitro* the hybrid cells are cultured with the immune cells of the patient and the activated cells are administered to the patient.

The results of *in vivo* treatment in mice as seen on page 60, line 10, of the specification indicate that the therapy may provide long-term tumor protection in cancer patients. Cancer therapy based on the elimination of tumor cells *in vivo* by the immune system offers several advantages including antigen specificity, lack of toxicity, ubiquity, and immunological memory which may provide long term resistance. The present application shows that somatic hybrid cells formed from the fusion of tumor cells and dendritic cells have the unexpected capacity to provide both antigenic and costimulatory signals to T-cells and to induce specific protection against the established parental tumor.

The invention provides a means of cancer treatment which has significant advantages over other cancer treatments and may provide an effective and long-lasting anti-tumor response *in vivo*. Therefore, Applicants are entitled to have this petition granted.

Applicants filed the fee set forth by 37 C.F.R. § 1.17(h), in accordance with 37 C.F.R. § 1.102(d), with the petition filed September 19, 2002. Thus, Applicants do not believe that additional fees are owed. However, should any fees be owed please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 24, 2002

By: Catherine M. Sanders
Catherine M. Sanders
Registration No. 50,660
Agent of Record
2040 Main Street
Fourteenth Floor
Irvine, CA 92614
(949) 760-0404



RECEIVED
OCT 01 2002
TECH CENTER 1600/2900

CP1633
PATENT

Case Docket No. DECLE55.1CP2DV
Date: September 24, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Moser, et al.
Appl. No. : 09/802,397
Filed : March 9, 2001
For : DENDRITIC-LIKE
CELL/TUMOR CELL
HYBRIDS AND
HYBRIDOMAS INDUCING
AN ANTI-TUMOR RESPONSE
Examiner : Unknown
Group Art Unit : 1633

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to: United States Patent and Trademark Office, P.O. Box
2327, Arlington, VA 22202, on

September 24, 2002

(Date)

Catherine M. Sanders
Catherine M. Sanders, Reg. No. 50,660

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Petition to Make Special Under 37 C.F.R. § 1.102(d).
- (X) Return prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Catherine M. Sanders
Catherine M. Sanders
Registration No. 50,660
Agent of Record